Download PDF
CC BY 4.0 · Brazilian Journal of Oncology 2019; 15: e-20190002
DOI: 10.5935/2526-8732.20190002
Case Report

Metastatic castration-resistant prostate cancer (mCRPC) treated with 225Ac-PSMA-617. Case report

Câncer de próstata metastático resistente à castração (mCRPC) tratado com 225Ac-PSMA-617. Relato de caso

Rodrigo Bovolin de Medeiros
1   Hospital Sírio-Libanês, Centro de Oncologia - Brasília - DF - Brazil
,
Marcus Vinicius Grigolon
2   Hospital Sírio-Libanês, Departamento de Medicina Nuclear - Brasília - DF - Brazil
,
Tatianny Paula Araújo
1   Hospital Sírio-Libanês, Centro de Oncologia - Brasília - DF - Brazil
,
Miguel Srougi
3   Universidade de São Paulo, Disciplina de Urologia - São Paulo - SP - Brazil
› Author Affiliations Financial support: none to declare.
› Further Information
   Permissions and Reprints All articles of this category

ABSTRACT

Metastatic castration-resistant prostate cancer (mCRPC) is an extremely severe disease that relentlessly evolves to death. Over the past few years, we have seen significant improvements in the different types of treatments available, which have positively impacted several clinical outcomes, including higher survival rates and better quality of life. Since Radium-223 approval by FDA in 2013, nuclear medicine has been incorporated to the therapeutic arsenal. Progress in this field have motivated a pursuit for new targeted therapies using radioactive isotopes. Recent reports addressing the first cases treated with this technique are impressive due to the high response rates obtained in refractory patients. Here we report the case of a patient with mCRPC who had been previously treated with several lines of anti-androgen therapy and cytotoxic chemotherapy, recently treated with PSMA labeled with the alpha-emitting radioisotope Actinium-225 (225 Ac).

RESUMO

O câncer de próstata metastático resistente à castração (mCRPC) é uma doença extremamente grave que evolui implacavelmente para a morte. Nos últimos anos, temos visto melhorias significativas nos diferentes tipos de tratamentos disponíveis, que têm um impacto positivo sobre vários desfechos clínicos, incluindo taxas mais elevadas de sobrevida e melhor qualidade de vida. Desde a aprovação do Radium-223 pela FDA em 2013, a medicina nuclear foi incorporada ao arsenal terapêutico. O progresso nesse campo motivou a busca por novas terapias direcionadas usando isótopos radioativos. Os relatos recentes que abordam os primeiros casos tratados com esta técnica são impressionantes, devido às altas taxas de resposta obtidas em pacientes refratários. Aqui apresentamos o caso de um paciente com mCRPC que tinha sido previamente tratado com várias linhas de terapias antiandrogênicas e quimioterapia citotóxica e recentemente tratado com o alfa radioisótopo Actínio-225 (225 Ac) marcado com PSMA.

Keywords:

Prostatic Neoplasms - Castration-Resistant - Nuclear Medicine - Alpha Particles

Descritores:

Neoplasias da Próstata - Resistentes à - Castração - Medicina nuclear - Partícula alfa

AUTHOR'S CONTRIBUTION

Rodrigo Bovolin de Medeiros: Collection and assembly of data, Conception and design, Data analysis and interpretation, Final approval of manuscript, Manuscript writing, Provision of study materials or patient.

Marcus Vinicius Grigolon: Collection and assembly of data, Conception and design, Data analysis and interpretation, Manuscript writing, Provision of study materials or patient.

Tatianny Paula Araújo: Collection and assembly of data.

Miguel Srougi: Final approval of manuscript, Provision of study materials or patient.




Publication History

Received: 05 August 2018

Accepted: 18 March 2019

Article published online:
15 April 2019

© 2022. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

Bibliographical Record
Rodrigo Bovolin de Medeiros, Marcus Vinicius Grigolon, Tatianny Paula Araújo, Miguel Srougi. Metastatic castration-resistant prostate cancer (mCRPC) treated with 225Ac-PSMA-617. Case report. Brazilian Journal of Oncology 2019; 15: e-20190002.
DOI: 10.5935/2526-8732.20190002
 

  • REFERENCES

  • Global Burden of Disease Cancer Collaboration. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H. et al Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol 2017; 3 (04) 524-548
    Search in Google Scholar
  • Brazil. Ministério da Saúde. Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2018: Incidência de Câncer no Brasil. Rio de Janeiro: Instituto Nacional de Câncer José Alencar Gomes da Silva;; 2018. [cited 2019 Jan 18]. Available from: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-incidencia-de-cancer-no-brasil-2018.pdf
    Search in Google Scholar
  • Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G. et al Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol 2016; 195 (05) 1436-1443
    Search in Google Scholar
  • Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD. et al ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. New Eng J Med 2013; 369 (03) 213-223
    Search in Google Scholar
  • Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A. et al 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur J Nucl Med Mol Imaging 2017; 44 (01) 81-91
    Search in Google Scholar
  • Buyyounouski MK, Choyke PL, McKenney JK, Sartor O, Sandler HM, Amin MB. et al Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67 (03) 245-253
    Search in Google Scholar
  • Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET. et al Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 (06) 649-655
    Search in Google Scholar
  • Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benešová M, Mier W. et al [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42 (06) 987-988
    Search in Google Scholar
  • Kulkarni HR, Singh A, Schuchardt C, Niepsch K, Sayeg M, Leshch Y. et al PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013. J Nucl Med 2016; 57 (Suppl 3): 97S-104S
    Search in Google Scholar
  • Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F. et al 225Ac-PSMA-617 for PSMA-Targeted a-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. J Nucl Med 2016; 57 (12) 1941-1944
    Search in Google Scholar
  • Wadas TJ, Pandya DN, Solingapuram Sai KK, Mintz A.. Molecular targeted a-particle therapy for oncologic applications. AJR Am J Roentgenol 2014; 203 (02) 253-260
    Search in Google Scholar
  • Nayak T, Norenberg J, Anderson T, Atcher R. A. comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro. Cancer Biother Radiopharm 2005; 20 (01) 52-57
    Search in Google Scholar
  • Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R. et al 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging 2014; 41 (11) 2106-2119
    Search in Google Scholar